The Committee For Medicinal Products For Human Use Of The European Medicines Agency Recommended The Approval Of Merck's Winrevair (Sotatercept) Combined With Other Pulmonary Arterial Hypertension (PAH) Therapies, For PAH In Adult Patients
Merck & Co., Inc. +0.24% Pre
Merck & Co., Inc. MRK | 104.23 104.40 | +0.24% +0.16% Pre |
, European Commission's Decision Is Expected In Q3